Skip to content
Home
About
Who we are
Our Team
Distill EDC
Benefits
Features
Pricing
Industry News
Latest
RWE
Clinical Trials
Oncology
SVM
Case Studies
Publications
Endorsements
Pricing
Contact
×
Home
About
Who we are
Our Team
Distill EDC
Benefits
Features
Pricing
Industry News
Latest
RWE
Clinical Trials
Oncology
SVM
Case Studies
Publications
Endorsements
Pricing
Contact
PUBLICATIONS
Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient– Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study
09 February 2022
READ MORE
Posts navigation
← A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis
Aztreonam Lysine (Cayston) →